Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 13/20 | 0.49 |
| ▸ | MAOA | P21397 | 12/20 | 0.49 |
| ▸ | MAOB | P27338 | 12/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15767768 | 1.00 | GAA (0.53) | GAASMN1; SMN2KDM1AMAOAMAOB | |
| Trifluoroacetic Acid SCHEMBL15667517 | 0.92 | GAA (0.47) | GAASMN1; SMN2KDM1AMAOAMAOB | |
| Trifluoroacetic Acid SCHEMBL15284412 | 0.89 | GAA (0.47) | GAASMN1; SMN2KDM1AMAOAMAOB | |
| SCHEMBL10083062 | 0.86 | PPARG (0.46) | KDM1AMAOAMAOB | |
| SCHEMBL28668280 | 0.85 | ABCC1 (0.51) | GAASMN1; SMN2KDM1A | |
| Hydrochloric Acid SCHEMBL3658022 | 0.84 | KDM1A (0.52) | GAASMN1; SMN2KDM1AKDM4E | |
| SCHEMBL903571 | 0.84 | MAOA (0.50) | KDM1AMAOAMAOB | |
| SCHEMBL2074431 | 0.83 | KDM1A (0.50) | KDM1AMAOAMAOB | |
| SCHEMBL2074430 | 0.83 | KDM1A (0.50) | KDM1AMAOAMAOB | |
| SCHEMBL28558069 | 0.81 | SMN1; SMN2 (0.56) | GAASMN1; SMN2KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193359-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160193359-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | SEATTLE GENETICS, INC. (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | SEATTLE GENETICS, INC. (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2621508-B1 | N-CARBOXYALKYL AURISTATINS AND THE USE THEREOF | SEATTLE GENETICS INC (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20150148298-A1 | N-CARBOXYALKYL-AURISTATIN AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148298-A1 | N-CARBOXYALKYL-AURISTATIN AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2015-05-28 | — | — | US | disclosed |
| US-8992932-B2 | Binder-drug conjugates (ADCs) and use thereof | SEATTLE GENETICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8992932-B2 | Binder-drug conjugates (ADCs) and use thereof | SEATTLE GENETICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8987209-B2 | N-carboxyalkyl-auristatin and the use thereof | SEATTLE GENETICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| WO-2013087716-A2 | NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-06-20 | — | — | WO | disclosed |
| US-20130122024-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20130122024-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | Bayer Pharma AG (DE) | 2013-04-18 | — | — | US | disclosed |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | Bayer Pharma AG (DE) | 2013-04-18 | — | — | US | disclosed |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| WO-2012143495-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143496-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012041805-A1 | N-CARBOXYALKYL AURISTATINS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130122024-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | MDN1, EPCAM, VCAM1 | GAA 1794/4885SMN1; SMN2 2778/4885KDM1A 2479/4885 |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | GAA 1606/4885SMN1; SMN2 4203/4885KDM1A 3254/4885 |
| US-20160193359-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | GAA 1606/4885SMN1; SMN2 4203/4885KDM1A 3254/4885 |
| US-20150148298-A1 | N-CARBOXYALKYL-AURISTATIN AND USE THEREOF | HDGF, HGFAC, HGF | GAA 1530/4885SMN1; SMN2 4376/4885KDM1A 3178/4885 |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | DDR1, IGFBP6, KDR | GAA 1381/4885SMN1; SMN2 4223/4885KDM1A 3109/4885 |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | CDK4, CDKL4, FLT4 | GAA 1606/4885SMN1; SMN2 4203/4885KDM1A 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.